Dual receptor blockade by bosentan: clinical experience in treatment of pulmonary hypertension

References

• Galiè N, Hoeper MM, Humbert M, et al. ESC/ERS GUIDELINES. Guidelines for the diagnosis and treatment of pulmonary hypertension. EurRespir J. 2009;34(6):1219–1263.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54 (1 Suppl S):S43–S54.
   Web of Science ®Google Scholar
• Perro F, Dorthmüller P, Souza R, et al. Dendritic cell recruitment in lesions of human an experimental pulmonary hypertension. Eur Respir J. 2007;29(3):462–468.
   Web of Science ®Google Scholar
• Montani D, Souza R, Binkert C, et al. Endothelin-1/endothelin-3 ratio: A potential prognostic factor of pulmonary arterial hypertension. Chest. 2007;131(1):101–108.
   Web of Science ®Google Scholar
• McLaughlin VV McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114(13):1417–1431.
   Web of Science ®Google Scholar
• Galie N, Manaes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61(2):227–237.
   PubMed Web of Science ®Google Scholar
• Frash HF, Marshall C, Marshall BE. Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Am J Physiol. 1999;276(2 Pt 1):304–310.
   Google Scholar
• Salani D, Di Castro V Nicotra MR, et al. Role of endothelin-1 in neovascularisation of ovarian carcinoma. Am J Pathol. 2000;157(5):1537–1547.
   Web of Science ®Google Scholar
• Wort SJ, Woods M, Warner TD, Evans TW, Mitchell JA. Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation. Am J Respir Cell Mol Biol. 2001 ;25(1):104–110.
   PubMed Web of Science ®Google Scholar
• Shi-Wen X, Chen Y, Denton CP, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell. 2004;15(6):2707–2719.
   PubMed Web of Science ®Google Scholar
• Hocher B, Schwarz A, Fagan DA, et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol. 2000;23(1):19–26.
   PubMed Web of Science ®Google Scholar
• Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation. 1996;94(7):1578–1584.
   PubMed Web of Science ®Google Scholar
• Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):13S–24S.
   PubMed Web of Science ®Google Scholar
• Brunner F. Cardiac endothelin and big endothelin in right-heart hypertrophy due to monocrotaline-induced pulmonary hypertension in rat. Cardiovasc Res. 1999;44(1):197–206.
   Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothe- lin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328(24):1732–1739.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Dorent R, Nataf P, et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res. 1997;33(1):196–200.
   Web of Science ®Google Scholar
• Nootens M, Kaufmann E, Rector T, et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995;26(7):1581–1585.
   Web of Science ®Google Scholar
• Yoshibayashi M, Nishioka K, Nakao K, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation. 1991;84(6):2280–2285.
   PubMed Web of Science ®Google Scholar
• Hiramoto Y, Shioyama W, Kuroda T, et al. Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension. Circ J. 2007;71(3):367–369.
   PubMed Web of Science ®Google Scholar
• Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002;165(3):398–405.
   PubMed Web of Science ®Google Scholar
• Brunner F, Wölkart G, Haleen S. Defective intracellular calcium handling in monocrotaline-induced right ventricular hypertrophy: Protective effect of long-term endothelin-A receptor blockade with 2-benzo[1,3]dioxol-5-yl-3-benzyl-4-(4-methoxy-phenyl-)-4-oxobut- 2-enoate-sodium (PD 155080). J Pharmacol Exp Ther. 2002;300(2):442–449.
   Web of Science ®Google Scholar
• Miyauchi T, Yorikane R, Sakai S, et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res. 1993;73(5):887–889.
   PubMed Web of Science ®Google Scholar
• Chen SJ, Chen YF, Opgenorth TJ, et al. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodelling in Sprague-Dawley rats. J Cardiovasc Pharmacol. 1997;29(6):713–725.
   PubMed Web of Science ®Google Scholar
• Hiramoto Y, Shioyama W, Higuchi K. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension. J Cardiol. 2009;53(3):374–380.
   Web of Science ®Google Scholar
• Jasmin JF, Lucas M, Cernacek P, Dupuis J. Effectiveness of a non-selective ETA/B and selective ETA antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation. 2001;103(2):314–318.
   Web of Science ®Google Scholar
• Williamson DJ, Wallman LL, Jones R, et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation. 2000;102(4):411–418.
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-control study. Lancet. 2001;358(9288):1119–1123.
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903.
   PubMed Web of Science ®Google Scholar
• Souza R, Jardim C, Martins B, et al. Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Curr Med Res Opin. 2005;21(6):907–911.
   PubMed Web of Science ®Google Scholar
• Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005;60(12):1025–1030.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Resp J. 2005;25(2):244–249.
   PubMed Web of Science ®Google Scholar
• Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: Improved survival in the current era. Heart. 2006;92(7):926–932.
   PubMed Web of Science ®Google Scholar
• Denton CP, Pope JE, Peter HH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis. 2008;67(9):1222–1228.
   Web of Science ®Google Scholar
• Galiè N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothe-lin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41(8):1380–1386.
   PubMed Web of Science ®Google Scholar
• Chin KM, Kingman M, Lemos JA, et al. Changes in right ventricular structure and function assessed using cardiar magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension. Am J Cardiol. 2008;101(11):1669–1672.
   Web of Science ®Google Scholar
• Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopul-monary hypertension. Eur Respir J. 2005;25(3):502–508.
   PubMed Web of Science ®Google Scholar
• Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48–54.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170(11):1212–1217.
   PubMed Web of Science ®Google Scholar
• Galie N, Rubin LJ, Hoeper MM, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial. Lancet. 2008;37(1):2093–2100.
   Google Scholar
• O’Callaghan D, Gaine S. Combination therapy and new types of agents for pulmonary hypertension. C Un Chest Med. 2007;28(1):169–185.
   Web of Science ®Google Scholar
• Austin MJ, McDougall NI, Wendon JA, et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl. 2008;14(3):287–291.
   PubMed Web of Science ®Google Scholar
• Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353–359.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J. 2003;22(2):330–334.
   PubMed Web of Science ®Google Scholar
• Seyfarth HJ, Pankau H, Hammerschidt S, Schauer J, Wirtz H, Winkler J. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoids treatment. Chest. 2005;128(2):709–713.
   Web of Science ®Google Scholar
• Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47(10):2049–2056.
   PubMed Web of Science ®Google Scholar
• Valerio CJ, Handler CE, Kabunga P, et al. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. Rheumatology. Jul 30, 2010. [Epub ahead of print].
   Web of Science ®Google Scholar
• McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009;135(1):122–129.
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am JResp Crit Care Med. 2005;171(11):1292–1297.
   Web of Science ®Google Scholar
• Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J. 2008;32(3):619–628.
   PubMed Web of Science ®Google Scholar
• Jardim C, Souza R. Pulmonary hypertension therapy and COPD: Still many questions to be answered. Eur Respir J. 2009;33(2):449.
   Google Scholar
• Valerio G, Bracciale P, Grazia D’Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2009;3(1):15–21.
   PubMedGoogle Scholar
• Hoper MM, Kramm T, Wilkens H, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005;128(4):2363–2367.
   Google Scholar
• Bonderman D, Nowotny R, Sajer-Skoro N, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005;128(4):2599–2603.
   PubMed Web of Science ®Google Scholar
• Vassallo FG, Kodric M, Scarduelli C, et al. Bosentan for patients with chronic thromboembolic pulmonary hypertension. Eur J Intern Med. 2009;20(1):24–29.
   Web of Science ®Google Scholar
• Jaïs X, D’Armini AM, Jansa P et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 2008;52(25):2127–2134.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S78–S84.
   PubMed Web of Science ®Google Scholar